Among all treatment groups, the improvement effect of PL was the most obvious, in which serum IL-1β, IL-18, and TNF-α were decreased by 18.87%, 17.93%, and 38.97%, respectively (vs. MG). The gene discussed is TNF; the disease is myasthenia gravis.